Mind the gap

Alternatives to Laboratory Animals

Volumn 38, Issue SUPPL. 1, 2010, Pages 1-4

  Aithal, Guruprasad P ^a  

^a NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

Animal models; DILI; Human primary cells; NAFLD; NASH

Indexed keywords

CHOLINE; FIALURIDINE; METHIONINE; METHOTREXATE; PIOGLITAZONE; PLACEBO; WARFARIN; XIMELAGATRAN;

ALCOHOL CONSUMPTION; ANIMAL MODEL; CHRONIC HEPATITIS; CONTROLLED CLINICAL TRIAL (TOPIC); ENVIRONMENT; HEPATITIS B; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; MULTIPLE ORGAN FAILURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SPRAGUE DAWLEY RAT; UNSPECIFIED SIDE EFFECT;

ANIMALIA;

EID: 79551696589     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291003801s01     Document Type: Short Survey

References (8)

1. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B. & Heller, A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology & Pharmacology 32, 56-67.
2. Lampertico, P., Malter, J.S. & Gerber, M.A. (1991). Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics. Hepatology 13, 422-426.
3. Stevenson, W., Gaffey, M., Ishitani, M., McCullough, C., Dickson, R., Caldwell, S., Lobo, P. & Pruett, T. (1995). Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. Transplant Proceedings 27, 1219-1221.
4. McKenzie, R., Fried, M.W., Sallie, R., Conjeevaram, H., Di Bisceglie, A.M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J.L., Straus, S.E. & Hoofnagle, J.H. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 333, 1099-1105.
5. Ainscow, E.K., Pilling, J.E., Brown, N.M., Orme, A.T., Sullivan, M., Hargreaves, A.C., Cooke, E.L., Sullivan, E., Carlsson, S. & Andersson, T.B. (2008). Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures. Expert Opinion on Drug Safety 7, 351-365.
6. Kindmark, A., Jawaid, A., Harbron, C.G., Barratt, B.J., Bengtsson, O.F., Andersson, T.B., Carlsson, S., Cederbrant, K.E., Gibson, N.J., Armstrong, M., Lagerström-Fermér, M.E., Dellsén, A., Brown, E.M., Thornton, M., Dukes, C., Jenkins, S.C., Firth, M.A., Harrod, G.O., Pinel, T.H., Billing-Clason, S.M., Cardon, L.R. & March, R.E. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics Journal 8, 186-195. (Pubitemid 351712643)
7. Robosky, L.C., Wells, D.F., Egnash, L.A., Manning, M.L., Reily, M.D. & Robertson, D.G. (2005). Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicological Sciences 87, 277-284. (Pubitemid 41222680)
8. Aithal, G.P., Thomas, J.A., Kaye, P.V., Lawson, A., Ryder, S.D., Spendlove, I., Austin, A.S., Freeman, J.G., Morgan, L. & Webber, J. (2008). Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastro-enterology 135, 1176-1184.